Join
Live feed
·
INSIDERFilingvia Quantisnow
Aprea Therapeutics Inc. logo

SEC Form 4: Gilad Oren converted options into 6,045,100 shares and was granted 4,000 shares, decreasing direct ownership by 2% to 322,770 units

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APRE (Aprea Therapeutics Inc.) and more on Quantisnow.